Source: http://www.readbag.com/accessdata-fda-cdrh-docs-pdf8-k081853
Timestamp: 2019-07-19 10:58:03
Document Index: 353061658

Matched Legal Cases: ['arts 800', 'art 8', 'art 801', 'art 820', 'art 801', 'art 807']

Read K081853.pdf
Read K081853.pdf text version
General Information Classification Trade Name Submitter Class II OverStitch Apollo Endosurgery, Inc. 7000 Bee Caves Road Suite 350 Austin, Texas 78746 Tel: (512) 328-9990 Contact Dennis McWilliams President &amp; CEO
Intended Use The Apollo Endosurgery OverStitch Endoscopic Suture System is intended for endoscopic placement of suture(s) and approximation of soft tissue. Predicate Devices K061770 K003956 K972911 Device Description The Apollo Endosurgery OverStitch Endoscopic Suture System provides physicians the ability to perform several different types of tissue apposition within the Gastrointestinal Endoscopic Suturing System (ESS) Ethicon Endo Surgery EndoCinch Suturing System Davol / Bard Auto Suture-Endo Stitch Tyco Healthcare
(GI) Tract and peritoneal cavity. Additionally, the system allows the surgeon to 'reload' the suture without the need for removing the endoscope. Materials All materials used in the manufacture of the OverStitch are suitable for this use and have been used in numerous previously cleared products. Testing Product testing was conducted to evaluate conformance to product specification. Testing included mechanical strength testing, bond strength, suture operation, suture securement and visual / dimensional inspection. Suture placement and securement testing was performed by comparing the OverStitch to commercially available predicate products. The products were used per their respective Instructions for Use. The results showed the OverStitch was equivalent to the predicate devices. Summary of Substantial Equivalence The OverStitch is equivalent to the predicate products. The indications for use, basic overall function, methods of manufacturing, and materials used are substantially equivalent.
Apollo Endosurgery, Inc. % Mr. Dennis McWilliams President &amp; CEO 7000 Bee Caves Road, Suite 350 Austin, Texas 78746
Re: K081853 Trade/Device Name: OverStitch Endoscopic Suturing System Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and accessories Regulatory Class: IL Product Code: OCW, 1tCF Dated: June 26, 2008 Received: June 30, 2008 Dear Mr. McWilliams: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced ab)ove and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 8C7); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Page 2 -Mr. Dennis McWilliams This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed pr-dicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological IHealth's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, &quot;Misbranding by reference to premarket notification&quot; (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http:/www. fda.ov/cdrh/industr/supportindex.html. Sincerely yours,
510(k) Number (if known): Device Name: OverStitch Endoscopic Suturing System
The Apollo Endosurgery OverStitch Endoscopic Suture System is intended for endoscopic placement of suture(s) and approximation of soft tissue.
X Prescription Use (Per 21 CFR 801.109)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
ce Evaluation (ODE)
. (DiviiOn SignROrt).
Division of General, Restoratve,
__________________Page